title: Plasma cells as an innovative target in autoimmune disease with renal manifestations.
abstract: Autoantibodies are secreted by plasma cells and have an essential role in driving the renal manifestations of autoimmune diseases such as systemic lupus erythematosus and antineutrophil cytoplasmic autoantibody-associated vasculitis. Effective depletion of autoreactive plasma cells might be the key to curative treatment of these diseases. Two major plasma-cell compartments exist: short-lived plasmablasts or plasma cells, which result from differentiation of activated B cells, and long-lived plasma cells, which result from secondary immune responses. Long-lived plasma cells reside in survival niches in bone marrow and inflamed tissue and provide the basis of humoral memory and refractory autoimmune disease activity. Unlike short-lived plasmablasts, long-lived plasma cells do not respond to conventional immunosuppression or to therapies that target B cells. Existing therapies that target long-lived plasma cells, such as proteasome inhibitors and antithymocyte globulin, as well as promising approaches that target survival factors, cell homing or surface molecules, deplete the whole memory plasma cell pool, including cells that secrete protective antibodies. By contrast, we have developed a novel strategy that uses an affinity matrix to deplete pathogenic long-lived plasma cells in an autoantigen-specific manner without removing protective plasma cells. Targeting B-cell precursors to prevent replenishment of autoreactive long-lived plasma cells should also be considered.
authors.affiliation: Charité - Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, ein Institut der Leibniz-Gemeinschaft, Charitéplatz 1, Berlin 10117, Germany.
authors.forename: Falk
authors.initials: F
authors.lastname: Hiepe
authors.affiliation: Charité - Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum Berlin, ein Institut der Leibniz-Gemeinschaft, Charitéplatz 1, Berlin 10117, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Radbruch
mesh_terms: D001323:Autoantibodies / Q000276:immunology*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy / Q000276:immunology*; D008181:Lupus Nephritis / Q000188:drug therapy / Q000276:immunology; D009842:Oligopeptides / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010950:Plasma Cells / Q000276:immunology*; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D013912:Threonine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D001323:Autoantibodies; D001897:Boronic Acids; C540323:CTCE-9908; D007166:Immunosuppressive Agents; D009842:Oligopeptides; D010455:Peptides; D061988:Proteasome Inhibitors; D013912:Threonine; D000069286:Bortezomib; C527966:delanzomib; C524865:carfilzomib